AI Arrhythmia Burden Analytics Market Report 2026

The artificial intelligence (AI) arrhythmia burden analytics market size has grown exponentially in recent years. It will grow from $1.68 billion in 2025 to $2.15 billion in 2026 at a compound annual growth rate (CAGR) of 28.2%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, growing adoption of wearable ecg monitors, increasing demand for early arrhythmia detection, expansion of remote patient monitoring platforms, and rising investment in digital health infrastructure.

The artificial intelligence (AI) arrhythmia burden analytics market size is expected to see exponential growth in the next few years. It will grow to $5.75 billion in 2030 at a compound annual growth rate (CAGR) of 27.9%. The growth in the forecast period can be attributed to increasing integration of AI in healthcare IT systems, growing focus on predictive and personalized cardiac care, rising cloud-based AI deployment, expansion of AI research and development, and increasing regulatory support for AI-driven medical devices. Major trends in the forecast period include innovation in predictive algorithms, advancement in cloud-based deployment, technology integration with wearable devices, investment in data analytics platforms, and development of AI-enabled diagnostic software.

The rising global prevalence of cardiovascular diseases and arrhythmias is expected to drive the growth of the artificial intelligence (AI) arrhythmia burden analytics market going forward. Cardiovascular diseases and arrhythmias encompass the increasing number of individuals worldwide affected by heart and blood vessel conditions, including irregular heart rhythms such as atrial fibrillation, which remain leading causes of death and disability globally. This rise in prevalence is attributed to aging populations and increased exposure to risk factors such as hypertension, obesity, and diabetes, which elevate the likelihood of arrhythmias. AI arrhythmia burden analytics supports the management of cardiovascular diseases and arrhythmias by enabling continuous, precise analysis of cardiac rhythm data, enhancing early detection and management of arrhythmic events. For instance, in August 2025, according to the Centers for Disease Control and Prevention, a Switzerland-based public health agency, 90% of the nation’s $4.9 trillion in annual healthcare spending is attributed to individuals with chronic and mental health conditions, with more than 84,000 Americans dying each year from heart disease or stroke. The costs associated with cardiovascular diseases are projected to reach roughly $2 trillion by 2050. Therefore, the rising global prevalence of cardiovascular diseases and arrhythmias is driving the growth of the AI arrhythmia burden analytics market.

The growing adoption of wearable and remote monitoring devices is also expected to propel the growth of the AI arrhythmia burden analytics market. Wearable and remote monitoring devices are electronic tools that continuously track an individual’s health or physiological parameters outside traditional clinical settings. Their use is increasing due to the rising number of patients with heart conditions, as continuous monitoring enables early detection and management of irregular heart rhythms. AI arrhythmia burden analytics enhances wearable and remote heart monitoring devices by leveraging artificial intelligence to process large volumes of cardiac data, detect irregular heart rhythms, quantify arrhythmia burden, and provide actionable insights to clinicians for timely interventions. For instance, in December 2025, according to Intuition Labs, a US-based healthcare technology company, nearly 50 million Americans are already using some form of remote patient monitoring device, 80% of Americans are favorable toward incorporating remote patient monitoring into medical care, and by 2025, over 71 million Americans - representing 26% of the population - are expected to use some form of remote patient monitoring service. Therefore, the growing use of wearable and remote heart monitoring devices is driving the growth of the AI arrhythmia burden analytics market.

Leading companies operating in the artificial intelligence (AI) arrhythmia burden analytics market are focusing on developing advanced products, such as AI-powered arrhythmia detection systems, to enhance diagnostic accuracy, improve patient compliance, and reduce the likelihood of misdiagnosis and repeat testing. AI-powered arrhythmia detection systems refer to sophisticated algorithms in cardiac monitors that automatically analyze continuous electrocardiogram (ECG) data to identify and classify irregular heart rhythms with clinical precision. For instance, in May 2025, iRhythm Technologies, a US-based digital health company, launched the Zio ECG Recording and Analysis System in Japan. It is a prescription-only, long-term continuous monitoring system featuring a deep-learning artificial intelligence (AI) algorithm approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). The system includes a patch-based monitor worn for up to 14 days and an analysis service that provides comprehensive reports, enabling seamless detection of 13 arrhythmia types without significant patient burden. It also incorporates certified clinical review and is associated with high diagnostic yield and low retesting rates, improving clinical efficiency for healthcare providers.

Major companies operating in the artificial intelligence (AI) arrhythmia burden analytics market are Medtronic plc, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Boston Scientific Corporation, iRhythm Technologies Inc., Bittium Corporation, Cardiac Rhythm Management, AliveCor Inc., VivaLNK Inc., Biotricity Inc., InfoBionic Inc., Cardiac Insight Inc., Cortrium ApS, Eko Health Inc., CardioComm Solutions Inc., Medi-Lynx Cardiac Monitoring LLC, QT Medical Inc., Wearable Sensors Ltd., HeartVista Inc., iCardiac Technologies Inc.

North America was the largest region in the artificial intelligence (AI) arrhythmia burden analytics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) arrhythmia burden analytics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) arrhythmia burden analytics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the ai arrhythmia burden analytics market by increasing costs of imported wearable sensors, monitoring hardware, cloud infrastructure components, and specialized computing equipment. healthcare providers and diagnostic centers in north america and europe are most affected due to reliance on advanced imported medical devices, while asia-pacific faces higher deployment costs for scalable monitoring solutions. these tariffs are increasing implementation expenses and slowing procurement cycles. however, they are also encouraging domestic development of analytics software, local device manufacturing, and regional digital health innovation ecosystems.

Artificial intelligence (AI) arrhythmia burden analytics refers to advanced technology that leverages AI to analyze cardiac arrhythmia patterns. It delivers insights into the frequency, duration, and severity of arrhythmias through data-driven algorithms. This solution enhances monitoring and provides predictive capabilities for more effective cardiac health management.

The main elements of AI arrhythmia burden analytics solutions include software, hardware, and services. Software consists of AI-powered analytics platforms that analyze heart rhythm data to detect arrhythmias, measure arrhythmia burden, and support clinical interpretation. These systems rely on technologies such as machine learning, deep learning, and natural language processing, and are deployed through on-premises and cloud-based models. They are used for arrhythmia detection, burden quantification, predictive risk assessment, treatment effectiveness monitoring, and clinical decision support by healthcare providers, diagnostic centers, academic institutions, and others.

The artificial intelligence (AI) arrhythmia burden analytics market includes revenues earned by entities by providing services such as data analysis services, predictive analytics solutions, real-time cardiac monitoring, AI-based risk assessment, and clinical decision support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The artificial intelligence arrhythmia burden analytics market consists of sales of AI arrhythmia detection software, cardiac monitoring devices, machine learning analytics platforms, wearable ECG monitors, and predictive risk assessment tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.